The story of Viagra presents a interesting case for stakeholders in the drug sector. While initially a tremendous success, producing vast sums, the exclusivity lapse and the subsequent arrival of off-brand alternatives have significantly affected revenue. This raises questions about the ongoing sustainability of similar therapeutic developments and